Novo Nordisk (NVO)

P/S ratio as of November 2026 (TTM): 3.52

According to Novo Nordisk's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 5.36. At the end of 2023 the company had a P/S ratio of 13.6.

P/S ratio history for Novo Nordisk from 2001 to 2023

PS ratio at the end of each year

Year	P/S ratio	Change
2023	13.6	12.21%
2022	12.2	4.89%
2021	11.6	40.15%
2020	8.27	8.61%
2019	7.61	19.98%
2018	6.35	-16.63%
2017	7.61	33.98%
2016	5.68	-40.33%
2015	9.52	31.16%
2014	7.26	6.83%
2013	6.79	1.79%
2012	6.68	22.64%
2011	5.44	-13.47%
2010	6.29	50.04%
2009	4.19	17.18%
2008	3.58	-32.99%
2007	5.34	33.24%
2006	4.01	21.24%
2005	3.31	-9.26%
2004	3.64	8.82%
2003	3.35	16.88%
2002	2.86	-28.15%
2001	3.99

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
Pfizer PFE	2.64	-25.09%	🇺🇸 USA
Eli Lilly LLY	14.8	320.43%	🇺🇸 USA
Sanofi SNY	1.98	-43.81%	🇫🇷 France
Bristol-Myers Squibb BMY	2.57	-27.02%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions

P/S ratio for Novo Nordisk (NVO)

P/S ratio as of November 2026 (TTM): 3.52